Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Metrodora Institute

- PMLiVE

FDA launches TEMPO digital health pilot

Digital technologies can improve remote patient care for those with chronic diseases

- PMLiVE

AstraZeneca and CSPC Pharmaceuticals enter AI-driven partnership worth $5.3bn

The deal will focus on advancing pre-clinical candidates for chronic conditions

- PMLiVE

Sanofi/Regeneron’s Dupixent shows significant improvements in paediatric eosinophilic oesophagitis

The chronic inflammatory disease affects approximately one in 2,000 people in the US

- PMLiVE

Eli Lilly to expand chronic disease pipeline with $3.2bn Morphic acquisition

The deal includes a candidate in mid-stage clinical development for inflammatory bowel disease

- PMLiVE

Eli Lilly to invest additional $5.3bn totalling $9bn in US manufacturing sites

The investment will provide an additional 200 jobs and more than 5,000 construction jobs during development of the site

- PMLiVE

NHS rolls out artificial pancreas for adults and children with type 1 diabetes in England

Type 1 diabetes accounts for approximately 10% of all diabetes cases in the UK

- PMLiVE

Researchers identify early treatment strategy for diabetic patients at risk of kidney disease

The chronic disease is currently the leading cause of kidney failure in the UK

- PMLiVE

Cambridge study reveals potential biomarker and target for long COVID treatments

The pro-inflammatory molecule, IFN-Y, persisted until symptoms improved in patients

- PMLiVE

PrecisionLife and Metrodora Institute partner for diagnosis and treatment of chronic diseases

The collaboration will first focus on developing products for long COVID and ME/CFS

- PMLiVE

Study finds vaccination against COVID-19 reduces long COVID symptoms

The results could help inform public health strategies and vaccination campaigns

- PMLiVE

Novo Nordisk announces $2.3bn investment to expand production site in France

The investment will increase the manufacturing capacity for Novo's GLP-1 products

- PMLiVE

Novo Nordisk Foundation commits €127m for new cell therapy facility

The new facility will help accelerate treatments for people living with chronic diseases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links